New hope for Tough-to-Treat lung cancer mutation
NCT ID NCT05466149
Summary
This study is testing an oral drug called furmonertinib for adults with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion) and has worsened after standard chemotherapy. The main goal is to see if the drug can shrink tumors and control the cancer. Researchers will also closely monitor side effects and how the drug works in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jilin Province Cancer Hospital
Changchun, Jilin, 130000, China
Conditions
Explore the condition pages connected to this study.